The invention generally relates to improvements to radioactive brachytherapy.
Tumors in living organisms are highly variable in size, location and their amount of infiltration into normal tissues, and the variability of tumors in general make them very difficult to treat with a one-size fits all approach. Furthermore, the extent of tumors and/or void created upon debulking are typically not known until presented in the operating room. Thus, the options necessary to effectively treat a tumor or tumor bed need to be quite diverse.
Brachytherapy involves placing a radiation source either into or immediately adjacent to a tumor. It provides an effective treatment of cancers of many body sites. Brachytherapy, as a component of multimodality cancer care, provides cost-effective treatment. Brachytherapy may be intracavitary, such as when treating gynecologic malignancies; intraluminal, such as when treating esophageal or lung cancers; external surface, such as when treating cancers of the skin, or interstitial, such as when treating various central nervous system tumors as well as extracranial tumors of the head and neck, lung, soft tissue, gynecologic sites, liver, prostate, and skin.
The systems, methods, and devices described herein each have several aspects, no single one of which is solely responsible for its desirable attributes. Without limiting the scope of this disclosure, several non-limiting features will now be described briefly.
As discussed herein, a transparent loading apparatus (also referred to herein as a “loader”) may comprise transparent material that allows light to pass through the loader and provides the viewer (whether manual or automated) a view of a seed carrier, radioactive seed, loading needle, etc. within the loading apparatus. In some embodiments, carrier material (e.g., collagen and/or other biocompatible material) and radioactive seeds (e.g., including a metal shielding and radioactive isotope) may transmit light to different degrees. For example, certain carriers, such as collagen carriers, may be translucent, while seeds may be opaque (or mostly opaque) to light. The systems discussed herein allow a viewer to detect location of a seed within a loader and even within a carrier because of these different light transmissivity characteristics.
The principles of the present invention will be apparent with reference to the following drawings, in which like reference numerals denote like components:
Although certain preferred embodiments and examples are disclosed below, inventive subject matter extends beyond the specifically disclosed embodiments to other alternative embodiments and/or uses and to modifications and equivalents thereof. Thus, the scope of the claims appended hereto is not limited by any of the particular embodiments described below. For example, in any method or process disclosed herein, the acts or operations of the method or process may be performed in any suitable sequence and are not necessarily limited to any particular disclosed sequence. Various operations may be described as multiple discrete operations in turn, in a manner that may be helpful in understanding certain embodiments; however, the order of description should not be construed to imply that these operations are order dependent. Additionally, the structures, systems, and/or devices described herein may be embodied as integrated components or as separate components. For purposes of comparing various embodiments, certain aspects and advantages of these embodiments are described. Not necessarily all such aspects or advantages are achieved by any particular embodiment. Thus, for example, various embodiments may be carried out in a manner that achieves or optimizes one advantage or group of advantages as taught herein without necessarily achieving other aspects or advantages as may also be taught or suggested herein.
Illustrative embodiments of the invention are described below. In the interest of clarity, not all features of an actual implementation are described in this specification. It will of course be appreciated that in the development of any such actual embodiment, numerous implementation-specific decisions must be made to achieve the developers' specific goals, such as compliance with system-related and business-related constraints, which will vary from one implementation to another. Moreover, it will be appreciated that such a development effort might be complex and time-consuming, but would nevertheless be a routine undertaking for those of ordinary skill in the art having the benefit of this disclosure.
Various embodiments of the loading apparatus are discussed herein, and any such embodiments may include one or more (up to all) surfaces that are transparent (or at least partially transparent). A “surface” generally refers to a substrate, e.g., an entire thickness of a top surface, but may refer to only a portion of a thickness of a substrate (e.g., a portion of a thickness of a top surface). Thus, if a particular loader includes a top surface, bottom surface, front surface, and end surface, any one or more of these surfaces may be transparent. For example, in one embodiment only the top surface and bottom surface are transparent, while in another embodiment each of the four surfaces are transparent. Advantageously, such transparent surfaces allow the viewer to know the seed position while it is still being positioned within the loader and, importantly, within the seed carrier. Thus, the seed may be positioned more precisely within the seed carrier. As used herein, the term “transparent” generally refers to the material that is at least partially transparent, which includes surfaces that are at least partially opaque also including surfaces that are not opaque. In some embodiments, a level of transparency is determined to be high enough to allow a human viewer and/or viewing apparatus (e.g., an imaging device) to detect position of the radioactive seed within the loader and, in some embodiments, within the seed carrier (e.g., the biocompatible material, such as collagen).
Definitions
In order to facilitate an understanding of the systems and methods discussed herein, a number of terms are defined below. The terms defined below, as well as other terms used herein, should be construed to include the provided definitions, the ordinary and customary meaning of the terms, and/or any other implied meaning for the respective terms. Thus, the definitions below do not limit the meaning of these terms, but only provide exemplary definitions.
Tumor: an abnormal growth of tissue resulting from uncontrolled, progressive multiplication of cells. Tumors can be benign or malignant.
Tumor bed: an anatomical area of a patient (e.g., a human or other mammal) where a tumor exists (pre-operative tumor bed) and/or an area surrounding a surgically removed tumor (post-operative tumor bed), such as a cranial cavity from which a tumor was surgically removed. Even after surgical removal of a tumor, the remaining tumor bed of the patient may include tumor cells.
Treatment area: an anatomical area that is targeted for delivery of radiation, such as from one or more radiation delivery devices (e.g., the carriers discussed below). A treatment area may include tissue below and/or around a location where the radiation deliver device is positioned, such as an anatomical area of a tumor or a tumor bed.
Treatment surface: an anatomical surface of a patient where a radiation delivery device is to be placed to deliver radiation to a treatment area, such as the treatment surface itself and/or tissue below the treatment surface. A treatment surface may be a portion of a tumor bed or any other anatomical surface. For example, if a tumor bed is surgically created, the treatment surface may include an entire exposed surface of the tumor bed, a portion of such exposed surface, or the entire exposed surface of the tumor bed as well as a surrounding area of tissue.
Brachytherapy: radiation treatment in which the radiation delivery device is placed directly on and/or close to a treatment surface of the body, such as directly on the surface of the body, within the body, or in a tumor bed. For example, brachytherapy may be intracavitary, such as in cranial or gynecologic malignancies; intraluminal, such as in esophageal or lung cancers; external, such as in cancers of the skin; and/or interstitial, such as in treatment of various central nervous system tumors as well as extracranial tumors of the head, neck, lung, soft tissue, gynecologic sites, rectum, liver, prostate, and penis.
Seed: a radioactive material that is configured for delivery of radiation to a tumor and/or tumor bed. A seed may be in various shapes and sizes, such as cylinder, cone, sphere, pyramid, cube, prism, rectangular prism, triangular prism, and/or any combination of these or other shapes. While seeds are generally referred to herein as cylindrical, any other shape or size of seed may alternatively be used in the various systems and methods discussed herein. Seeds may comprise any combination of one or more of multiple radioactive components, such as Cs 131, Ir 192, I 125, Pd 103, for example. Seeds may include a protective outer shell that partially or fully encases the radioactive material. Seeds are one form of radiation source. The term “radiation source,” as used herein, generally refers to a radioactive seed (or other object that emits radiation), either alone (e.g., a seed) or embedded, or otherwise attached to, a carrier (e.g., a tile carrier with an embedded radioactive seed).
Carrier: a substrate that holds or contains a radioactive seed. A carrier that contains one or more seeds is a radiation delivery device. Carriers may comprise various materials, such as one or more biocompatible materials including collagen. Carriers may be configured for permanent implantation into a tumor bed, such as to provide radioactive energy to a treatment surface surrounding an area where a tumor has been removed in order to treat any remaining malignant tissue. Carriers can be composed of various materials and take on various shapes and sizes. Examples carriers, such as carriers having various sizes, shapes, configurations, etc., are included in the following patent and patent application, each of which is hereby incorporated by reference in its entirety and for all purposes:
Tile Carrier (also referred to as “Tile”): type of carrier that is substantially planar and generally maintains a two-dimensional planar geometry when placed in a tumor bed. Depending on the material of the tile, though, the tile may be malleable such that the tile can be deformed by bending in order to better conform to a tumor bed. For example, for tiles comprising essentially collagen (and/or other malleable materials), the tiles may be substantially bent as placed in or on a treatment surface (and/or when pressed against the treatment surface) to conform with the shape of the treatment surface, such as a post-operative tumor bed.
Gore Carrier (also referred to as “Gore”): type of carrier that is 3-dimensional and conforms to the tumor bed while maintaining the geometry necessary for an effective implant. In some embodiments, gores are initially planar and are reconfigured to take on a 3-dimensional shape, such as to form a hemispherical surface that may be placed into a similarly shaped tumor cavity.
Star Carrier (also referred to as “Star” or “arm-based carrier”): type of carrier that assumes a conformable 3-dimensional shape when arranged and placed into an operative cavity or similar space and conforms to the treatment environment while maintaining the geometry necessary for an effective implant. However, in some embodiments, Star carriers may be used in their initial planar state to cover a relatively flat tumor or tumor bed area.
Loader: a device that aids in placement of radioactive seeds in carriers, such as via injection of seeds into carriers. A loader, also referred to herein as a “loading device,” may include multiple components, such as to hold a carrier in place and guide a delivery device (e.g., a needle or injector) into the carrier in order to place a seed at a precise location in the carrier. U.S. patent application Ser. No. 13/460,809, filed Apr. 30, 2012, now U.S. Pat. No. 8,939,881, entitled “Apparatus For Loading Dosimetrically Customizable Brachytherapy Carriers,” and U.S. patent application Ser. No. 14/696,293, filed Apr. 24, 2015, entitled “Apparatus and Method for Loading Radioactive Seeds Into Carriers,” which are each hereby incorporated by reference in their entirety for all purposes, describe several embodiments of loaders. As discussed further herein, loaders may be operated manually, such as by human operators, or may be fully automated, such that carriers can be loaded with seeds using an automated process. Alternatively, loaders may be configured to be automated in part and require manual operation in part.
Shielding Material: any material that restricts movement of radioactive particles, such as by absorbing, reflecting, and/or scattering radioactive particles. The term “shielding,” as used herein, generally refers to any mechanism of preventing radiation from moving through and exiting a corresponding shielding material, such as by the shielding material absorbing, reflecting, or otherwise blocking the radiation. Shielding materials in various forms may be used in the various embodiments discussed herein. For example, a shielding material may be in the form of a particle, wire, rod, cylinder, bar, sheet, liquid, solution, foam, or any other form in which a material having radiation absorbing and/or reflecting properties is possible. A shielding material provides a shielding rate, which is generally an amount of shielding of radioactive energy (that is emitted from one or more radiation sources), provided by the particular shielding materials. Similarly, a shielding layer comprising multiple shielding materials and an isolation sheet have associated shielding rates, which are dependent on the combination of shielding (and possibly non-shielding) materials therein. For some applications, such as based on clinical need, an isolation sheet that provides a shielding rate of 25%, 50%, 75%, 90%, 95%, 98%, or some other shielding percentage, may be desired. As discussed herein, material composition, shape, size, dimensions, etc. may impact the shielding abilities of a shielding material. For applications (e.g., based on clinical need) where a higher shielding percentage is desired than may be provided by a single shielding material, multiple shielding materials may be used in combination, in one or more shielding layers or isolation sheets.
In some embodiments, shielding materials comprise high Z materials, such as tantalum, gold, platinum, tin, steel, copper, aluminum, etc. (e.g., a 0.05 mm to 0.2 mm thickness metallic foil). In other embodiments, any other material that reduces penetration of radiation may be a shielding material. For example, a non-metallic, yet dense compound, may be used alone (or in combination with a metallic material) as a shielding material. Such a non-metallic shielding material may advantageously lessen the chance of 1) MRI artifacts, 2) deflection of the isolation sheet, and/or 3) MRI-induced heating, such as may be caused by current loop induction and/or radio-frequency induced tissue heating that may be caused by metallic shielding materials. Depending on the particular non-metallic material, thickness of the material may be larger than a required thickness of a metallic shielding material, in view of the general enhanced shielding abilities of metallic materials. Non-metallic high density shielding materials may beneficially provide shielding of non-target tissues from radiation particularly in applications where MRI or other magnetic field exposure may be anticipated. Examples of non-metallic shielding materials include polyetheretherketone (PEEK), nanoparticles, polymeric nanoparticles, encapsulated nanoparticles, calcium carbonate, calcium phosphate, calcium sulfate, barium sulfate, zirconium dioxide, polymers and polymer hybrids of these and other materials. Shielding materials may be combined to form a composite shielding material. For example, a metallic cylinder may be filled with (non-metallic) liquid calcium carbonate, in order to form a shielding material that better addresses one or more of the clinical needs of the patient than a separate metallic cylinder and liquid calcium carbonate or a solid metallic rod.
High Z Materials: any element with an atomic number greater than 20, or an alloy containing such materials.
Teletherapy generally refers to radiation treatment in which the source of the radiation is at a distance from the body.
High Dose Rate generally refers to treatment with radiation doses above 12,000 cGy/hr.
Low Dose Rate generally refers to treatment with radiation in the dose range of 400-2000 cGy/hr.
Hot generally refers to a material that is Radioactive, while Cold generally refers to a material that having no or low in radioactivity.
Dosimetry generally refers to the process of measurement and quantitative description of the radiation absorbed dose (rad) in a tissue or organ.
Transparent generally refers to a characteristic of a material that allows light to pass through the material such at least some of the light is visible by a human (e.g., visible light) and/or detectable by a machine (e.g., infrared light). A transparent material is at least partially transparent. Thus, some transparent surfaces are partially opaque, while others are not opaque at all. In some embodiments, a level of transparency is determined to be high enough to allow a human viewer and/or viewing apparatus (e.g., an imaging device) to detect position of a radioactive seed within the loader and, in some embodiments, within a seed carrier (e.g., the biocompatible material, such as collagen) positioned in the loader.
Carrier Systems
Generally the carrier systems described herein involve the utilization of small individual implantable carriers in the form of gores (e.g., gore carrier 1000 in a loader 300 in
The carrier systems are designed to create a carrier which allows for more precise and stable dosimetry; an improved geometry with a better orientation of seeds to one another especially in the settings of real-time, intraoperative environments; are fully customizable to size/volume, location, and tumor type; and/or can provide differential dosing of tumor/tumor bed vs. normal tissues.
Loading Devices
The embodied loaders can be single or multi-use, sterilizable, and shielded if desired. They are designed to load either standard or high-Z material carriers in an accurate, efficient, and real-time manner. The loaders are of similar designs, dimensionally specific, and each comprises at least two components, the base and the lid.
The loader designs of the present invention can be made to accommodate a wide variety of carrier dimensions and styles. They are illustrated to accommodate seed-in-suture, but can be easily adapted for loose seeds or other configurations.
When loading a seed in suture a needle longer than the loader may be used and pulled through the loader channel holes on the proximal end of the base and the distal of the lid. Once the needle protrudes it may be pulled the rest of the way with clamps, needle-nose plier, or another tool (such as an automated robotic tool). One example is wherein you have a 60 mm loader you may want to use a 70 mm (or longer) needle to feed through the loader channels and deposit the seeds within the carrier.
Example Tile Loader System
In one embodiment, a loader comprises a sterilizable single or multi-use device for manual or automated loading (in real time or for pre-loading) of carriers such as but not limited to tiles, gores, or stars with radioactive seeds such as I125, Cs131, Pd111, Pd103 and/or other materials. The loaders may be constructed of metal, plastic or composite material, and manufactured by casting, molding, stamping, forming or 3D printing. Embodiments of the loaders contemplated may include shielding either by way of construction with a high Z material, or with other materials with a sufficient dimension (thickness) to provide the necessary dose attenuation for a user.
Alternative embodiments may remain unshielded, and be made of materials suitable for the purpose including but not limited to tungsten, stainless steel, nylon or plastic.
The embodied Loader device generally has two components, a base and a lid. But each component has multiple and specialized functions when used to load radionuclide carriers. In some embodiments, loaders may include only the top and bottom surface, such as planar surfaces, that engage with a carrier while a CD is implanted within the carrier. For example, an automated system may include one or more automated movable surfaces, such as a top plate that moves up and down using hydraulic, electronic, or manual energy, to selectively engage a carrier that is placed on a lower surface.
In some embodiments, loaders comprise a base or “bed” that defines a space into which a preformed radionuclide or brachytherapy carrier (e.g., a tile, gore, star, or other carrier) is placed. This bed area is of a fixed dimension specific to the loader, and loaders are contemplated in multiple sizes identified for this purpose by the bed size. Bed sizes contemplated may be almost any dimension, such as between 1 cm×1 cm to 4 cm×4 cm (for example 1×2 cm, 2×3 cm and 3×4 cm). In some embodiments, bed sizes are even larger, such as 5×5 cm, 10×10 cm, or larger.
The base of the loaders function to: 1) guide the initial path of the loading needle for seed placement in the carrier; 2) provide dimensional stability to the soft carrier during the loading process; 3) center the carrier left-right within the base during the loading process; and 4) shield the user.
The “structure” of the base comprises a portion with an internal tunnel of appropriate length and diameter (e.g. 20 mm×I.2 mm) which guides the initial path of the loading needle for accurate seed placement in the carrier; and 2) sufficient material to constrain the carrier in the bed on 4 sides with; 3) exterior dimensions which may vary with the material/construction materials used; and 4) the need for a shielded or unshielded device.
An exemplary base of a loader device 100 is shown in
In some embodiments, loaders include a lid that may be configured to: 1) guide the final path of the loading needle, entirely through the carrier; 2) provide dimensional stability to the soft carrier during the loading process; 3) position the carrier superior-inferiorly within the base during the loading process; 4) position the carrier front to back within the base during the loading process; and/or 5) shield the user.
An additional aspect of the lid may be to function as a guide for the terminal path of the loading needle through the specific placement of an opening along its far aspect to accept the tip of the loading needle and thereby assure accurate placement of the seeds. Lids is conceived of as being made of as a set for each standard base so that, as an example, a 1×4 cm base can be used to load a 1×2 cm, 1×3 cm, or 1×4 cm carrier by utilizing a lid of appropriate length.
A further feature of this design is that there is a “tooth” on the end of the less than full length lids which add further stability when loading shorter length carriers.
An exemplary lid of a loader device 100 is shown in
Another loading device which allows for variable customization is shown in
In some embodiments, bed liners may include scorings, markings, or other indicators that provide information to the user as to the location of a carrier and/or seed(s) on the loader. For example, utility of a loader may be modified to enable quality control of seeds already placed in a carrier using such a bed liner, either in realtime as the seeds are being placed and/or as part of a quality assurance process. For example, a bed liner insert (placed in a loader) with markings at 0.8 cm, 1.0 cm or 1.2 cm on center would allow the manufacture or quality assurance monitoring of various seed placements (such as seeds that were previously placed in the same or a separate loader). Depending on the embodiment, these bed liners, as well as the bed, may include at least a portion that is at least partially transparent.
When a needle loading apparatus is used to load the radioactive seeds into the carriers such as that described in
Example Transparent Loader Surfaces
As discussed above, in some embodiments a loader may include one or more surfaces (e.g., one or more of the various bases, lids, bedliners, etc.) composed of a transparent material, where transparency is defined to include embodiments with various levels of transparency, from fully transparent to partially transparent. In some embodiments, a level of transparency is determined or selected to provide suitable visibility to a radioactive seed position behind the transparent surface. Thus, depending on the embodiment, the level of transparency required to provide this advantage may vary. For example, if the seed location is detected by human vision, such as by a technician or surgeon that manually handles the loader and monitors position of the seed within the loader, the transparency level may be higher than if the seed location is monitored with a digital detector (e.g., a camera or sensor) that monitors and automatically detects light, whether in the visible or invisible spectrum (e.g., with object detection software executing on a computing device).
In some embodiments, the level of transparency may also be determined or selected to provide suitable shielding of radioactive energy from radioactive seeds or other sources that are placed behind the transparent surface. For example, in some embodiments the transparent material may be impregnated with lead or another material that absorbs or reflects radioactive energy. In embodiments where a human user is handling the loader, the level of radioactive shielding may be increased to reduce radiation absorbed by the user's tissue. Conversely, in a loader system where seeds are inserted into carriers using robotic components, for example, radioactive shielding requirements may be reduced.
Depending on the embodiment, the transparent loader surfaces may be formed of various materials, such as glass, plastic, etc. Such materials may allow shielding objects to be implanted within the material, such as via an injection molding process. Depending on the embodiment, shielding material may be formed above, below, or within a transparent surface of a loader in various manners. For example, in some embodiments a thin layer of high Z foil may be placed above and/or below a transparent surface, such as across an entire area of the transparent surface or a portion of the transparent surface. For example, a suitable shielding level may be obtained by use of a shielding material across the portion of a transparent surface of a loader, while still providing a suitable level of visibility beyond the transparent surface.
In the example of
Possible advantages associated with use of a transparent loader (including a loader with one or more transparent surfaces) may include, but are not limited to:
The advantages discussed herein are not reliant on the loader providing any particular level of shielding or any shielding at all. For example, in some implementations external shielding around a loader could be provided. For example, a loader may include transparent material in various configurations, without specifically providing radiation shielding (e.g., the transparent materials may inherently provide some minimal level of radiation shielding, but extra shielding materials are not added to the loader specifically for shielding purposes). In one example, such as in the case of a human performing insertion of seeds into carriers in a production environment, the person may be shielded from radiation from the seeds before they are inserted into the loader and from the seeds in the collagen after removal from the loader by, e.g., a shielded workbench with lead glass or a camera/monitor and radiation hand protection.
Although the invention has been described with reference to the above examples, it will be understood that modifications and variations are encompassed within the spirit and scope of the invention.
Conditional language, such as, among others, “can,” “could,” “might,” or “may,” unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and/or steps. Thus, such conditional language is not generally intended to imply that features, elements and/or steps are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without user input or prompting, whether these features, elements and/or steps are included or are to be performed in any particular embodiment.
It should be emphasized that many variations and modifications may be made to the above-described embodiments, the elements of which are to be understood as being among other acceptable examples. All such modifications and variations are intended to be included herein within the scope of this disclosure. The foregoing description details certain embodiments of the invention. It will be appreciated, however, that no matter how detailed the foregoing appears in text, the invention can be practiced in many ways. As is also stated above, the use of particular terminology when describing certain features or aspects of the invention should not be taken to imply that the terminology is being re-defined herein to be restricted to including any specific characteristics of the features or aspects of the invention with which that terminology is associated. The scope of the invention should therefore be construed in accordance with the appended claims and any equivalents thereof.
This application is a continuation of U.S. application Ser. No. 15/824,182, filed on Nov. 28, 2017, which is a non-provisional of and claims priority to U.S. Provisional Patent Application No. 62/427,456, filed Nov. 29, 2016, entitled “TRANSPARENT LOADING APPARATUS.” The disclosure of the foregoing application is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
D244393 | Collica et al. | May 1977 | S |
4509506 | Windorski et al. | Apr 1985 | A |
4706652 | Horowitz | Nov 1987 | A |
4754745 | Horowitz | Jul 1988 | A |
4946435 | Suthanthiran et al. | Aug 1990 | A |
5030195 | Nardi | Jul 1991 | A |
D381080 | Ohata | Jul 1997 | S |
5772574 | Nanko | Jun 1998 | A |
5803895 | Kronholz et al. | Sep 1998 | A |
5840008 | Klein et al. | Nov 1998 | A |
5871708 | Park et al. | Feb 1999 | A |
D408957 | Sandor | Apr 1999 | S |
5967966 | Kronholz et al. | Oct 1999 | A |
5997842 | Chen | Dec 1999 | A |
6017482 | Anders et al. | Jan 2000 | A |
D420452 | Cardy | Feb 2000 | S |
D420745 | Cardy | Feb 2000 | S |
D420746 | Cardy | Feb 2000 | S |
6066302 | Bray | May 2000 | A |
6129670 | Burdette et al. | Oct 2000 | A |
D443061 | Bergstrom et al. | May 2001 | S |
6248057 | Mavity et al. | Jun 2001 | B1 |
6327490 | Spetz | Dec 2001 | B1 |
6352500 | Halpern | Mar 2002 | B1 |
6358195 | Green et al. | Mar 2002 | B1 |
6360116 | Jackson et al. | Mar 2002 | B1 |
6385477 | Werner et al. | May 2002 | B1 |
6450937 | Mercereau et al. | Sep 2002 | B1 |
6471631 | Slater et al. | Oct 2002 | B1 |
6512943 | Kelcz | Jan 2003 | B1 |
6539247 | Spetz | Mar 2003 | B2 |
6547816 | O'Foghludha | Apr 2003 | B1 |
6572526 | Ford | Jun 2003 | B1 |
6666811 | Good | Dec 2003 | B1 |
6679824 | Reed et al. | Jan 2004 | B1 |
6712508 | Nilsson et al. | Mar 2004 | B2 |
6712782 | Ford | Mar 2004 | B2 |
D488864 | Fago et al. | Apr 2004 | S |
6770021 | Halpern | Aug 2004 | B2 |
6787042 | Bond et al. | Sep 2004 | B2 |
6790170 | Moody et al. | Sep 2004 | B2 |
6846282 | Ford | Jan 2005 | B1 |
6994688 | Brauckman et al. | Feb 2006 | B2 |
7011619 | Lewis | Mar 2006 | B1 |
7070554 | White et al. | Jul 2006 | B2 |
7118729 | O'Foghludha | Oct 2006 | B1 |
7190895 | Groves et al. | Mar 2007 | B1 |
D561896 | Jones | Feb 2008 | S |
7410458 | Bray et al. | Aug 2008 | B2 |
D580056 | Orthner | Nov 2008 | S |
D580057 | Ramadani | Nov 2008 | S |
7686756 | Black et al. | Mar 2010 | B2 |
7736293 | Lamoureux et al. | Jun 2010 | B2 |
7749151 | Ferguson | Jul 2010 | B2 |
7776310 | Kaplan | Aug 2010 | B2 |
7972261 | Lamoureux et al. | Jul 2011 | B2 |
8012455 | O'Foghludha | Sep 2011 | B2 |
8021291 | Lamoureux et al. | Sep 2011 | B2 |
8039790 | Cho et al. | Oct 2011 | B2 |
8097236 | Aston et al. | Jan 2012 | B2 |
8114007 | Lamoureux et al. | Feb 2012 | B2 |
D657474 | Dona | Apr 2012 | S |
8187159 | Lamoureux et al. | May 2012 | B2 |
8192345 | Lamoureux et al. | Jun 2012 | B2 |
8226539 | Cutrer | Jul 2012 | B2 |
8293630 | Dunkley et al. | Oct 2012 | B2 |
8323172 | Black et al. | Dec 2012 | B2 |
8366598 | Lamoureux et al. | Feb 2013 | B2 |
D680649 | Jagger et al. | Apr 2013 | S |
D681210 | Beiriger et al. | Apr 2013 | S |
D681812 | Farris et al. | May 2013 | S |
D681813 | Jagger et al. | May 2013 | S |
8454489 | Drobnik et al. | Jun 2013 | B2 |
D686341 | Nakaji et al. | Jul 2013 | S |
D686744 | Nakaji et al. | Jul 2013 | S |
D686745 | Nakaji et al. | Jul 2013 | S |
D686746 | Nakaji et al. | Jul 2013 | S |
D686747 | Nakaji et al. | Jul 2013 | S |
D686748 | Nakaji et al. | Jul 2013 | S |
D687568 | Nakaji et al. | Aug 2013 | S |
D687966 | Nakaji et al. | Aug 2013 | S |
D687967 | Nakaji et al. | Aug 2013 | S |
8600130 | Eriksson Järliden | Dec 2013 | B2 |
8605966 | Eriksson Järliden | Dec 2013 | B2 |
8647603 | Aston et al. | Feb 2014 | B2 |
8771162 | Lamoureux et al. | Jul 2014 | B2 |
8790235 | Lamoureux et al. | Jul 2014 | B2 |
8795146 | Lamoureux et al. | Aug 2014 | B2 |
8825136 | Giller et al. | Sep 2014 | B2 |
8827884 | Ribbing et al. | Sep 2014 | B2 |
8834837 | Kelson et al. | Sep 2014 | B2 |
8876684 | Nakaji et al. | Nov 2014 | B1 |
8878464 | Clayton et al. | Nov 2014 | B2 |
8894969 | Kelson et al. | Nov 2014 | B2 |
8915834 | Lamoureux et al. | Dec 2014 | B1 |
8939881 | Nakaji et al. | Jan 2015 | B2 |
8974364 | Nakaji et al. | Mar 2015 | B1 |
9022914 | Clayton et al. | May 2015 | B2 |
9022915 | Nakaji et al. | May 2015 | B2 |
9180310 | Black et al. | Nov 2015 | B2 |
9358377 | Black et al. | Jun 2016 | B2 |
9403033 | Brachman | Aug 2016 | B1 |
9409038 | Nakaji et al. | Aug 2016 | B2 |
9492683 | Brachman et al. | Nov 2016 | B2 |
9526463 | Brachman et al. | Dec 2016 | B2 |
9545525 | Nakaji et al. | Jan 2017 | B2 |
9642999 | Sutton et al. | May 2017 | B2 |
9788909 | Larkin et al. | Oct 2017 | B2 |
9789608 | Itkowitz et al. | Oct 2017 | B2 |
9808650 | White et al. | Nov 2017 | B2 |
9821174 | Fram et al. | Nov 2017 | B1 |
10058713 | Kelson et al. | Aug 2018 | B2 |
10080909 | Brachman et al. | Sep 2018 | B2 |
10085699 | Brachman et al. | Oct 2018 | B2 |
10265542 | Brachman et al. | Apr 2019 | B2 |
10328278 | Krachon et al. | Jun 2019 | B2 |
10350431 | Nakaji et al. | Jul 2019 | B2 |
10449386 | Bask et al. | Oct 2019 | B2 |
10646724 | Hoedl et al. | May 2020 | B2 |
10888710 | Brachman et al. | Jan 2021 | B1 |
10981018 | Baker et al. | Apr 2021 | B2 |
11278736 | Brachman et al. | Mar 2022 | B2 |
11298846 | Hanberg et al. | Apr 2022 | B1 |
20010044567 | Zamora et al. | Nov 2001 | A1 |
20020055666 | Hunter | May 2002 | A1 |
20020058854 | Reed et al. | May 2002 | A1 |
20020120174 | Steele, Sr. et al. | Aug 2002 | A1 |
20030045769 | Kalas et al. | Mar 2003 | A1 |
20030088141 | Terwilliger et al. | May 2003 | A1 |
20030109769 | Lowery et al. | Jun 2003 | A1 |
20030113359 | Iyer et al. | Jun 2003 | A1 |
20030130573 | Yu et al. | Jul 2003 | A1 |
20030149329 | O'Foghludha | Aug 2003 | A1 |
20030208096 | Tam | Nov 2003 | A1 |
20040091421 | Aston et al. | May 2004 | A1 |
20040109823 | Kaplan | Jun 2004 | A1 |
20040116767 | Lebovic et al. | Jun 2004 | A1 |
20040225176 | Flanagan | Nov 2004 | A1 |
20040242953 | Good | Dec 2004 | A1 |
20050035310 | Drobnik et al. | Feb 2005 | A1 |
20050111621 | Riker et al. | May 2005 | A1 |
20050244045 | Eriksson | Nov 2005 | A1 |
20050267319 | White et al. | Dec 2005 | A1 |
20060015030 | Poulin et al. | Jan 2006 | A1 |
20060063962 | Drobnik et al. | Mar 2006 | A1 |
20060173236 | White et al. | Aug 2006 | A1 |
20060235365 | Terwilliger | Oct 2006 | A1 |
20060253048 | Jones | Nov 2006 | A1 |
20070135673 | Elliott et al. | Jun 2007 | A1 |
20070167665 | Hermann et al. | Jul 2007 | A1 |
20070190761 | Dunkley et al. | Aug 2007 | A1 |
20070225544 | Vance et al. | Sep 2007 | A1 |
20080004714 | Lieberman | Jan 2008 | A1 |
20080009661 | Lamoureux et al. | Jan 2008 | A1 |
20080058580 | Black et al. | Mar 2008 | A1 |
20080146861 | Murphy et al. | Jun 2008 | A1 |
20080221384 | Chi Sing et al. | Sep 2008 | A1 |
20090012347 | Helle | Jan 2009 | A1 |
20090069625 | Helle et al. | Mar 2009 | A1 |
20090131735 | Drobnik et al. | May 2009 | A1 |
20090136422 | Kelson et al. | May 2009 | A1 |
20090156880 | Allan et al. | Jun 2009 | A1 |
20090253950 | Rapach et al. | Oct 2009 | A1 |
20090271715 | Tumuluri | Oct 2009 | A1 |
20090275793 | Black et al. | Nov 2009 | A1 |
20100015042 | Keisari et al. | Jan 2010 | A1 |
20100056908 | Giller et al. | Mar 2010 | A1 |
20100200778 | Drobnik et al. | Aug 2010 | A1 |
20100228074 | Drobnik et al. | Sep 2010 | A1 |
20100268015 | Drobnik et al. | Oct 2010 | A1 |
20100288916 | Cho et al. | Nov 2010 | A1 |
20100324353 | Helle | Dec 2010 | A1 |
20110013818 | Eriksson Järliden | Jan 2011 | A1 |
20110206252 | Eriksson Järliden | Aug 2011 | A1 |
20120108882 | Hoedl | May 2012 | A1 |
20120165957 | Everland et al. | Jun 2012 | A1 |
20130102832 | Hoedl et al. | Apr 2013 | A1 |
20130102891 | Binnekamp et al. | Apr 2013 | A1 |
20130131434 | Nakaji et al. | May 2013 | A1 |
20130209965 | Fisker | Aug 2013 | A1 |
20130338423 | Nakaji et al. | Dec 2013 | A1 |
20140275715 | Brachman et al. | Sep 2014 | A1 |
20140296612 | Schwartz | Oct 2014 | A1 |
20140316187 | Nakaji et al. | Oct 2014 | A1 |
20150057487 | Nakaji et al. | Feb 2015 | A1 |
20150105605 | Finger et al. | Apr 2015 | A1 |
20150140535 | Geri et al. | May 2015 | A1 |
20150157879 | Wu et al. | Jun 2015 | A1 |
20150196778 | Nakaji et al. | Jul 2015 | A1 |
20150321024 | Nakaji et al. | Nov 2015 | A1 |
20150367144 | Flynn et al. | Dec 2015 | A1 |
20160242855 | Fichtinger et al. | Aug 2016 | A1 |
20160367709 | Aston et al. | Dec 2016 | A1 |
20170021191 | Brachman et al. | Jan 2017 | A1 |
20170120073 | Brachman et al. | May 2017 | A1 |
20170215824 | Brachman et al. | Aug 2017 | A1 |
20170252575 | Nakaji et al. | Sep 2017 | A1 |
20180333509 | Aston et al. | Nov 2018 | A1 |
20180345038 | Kelson et al. | Dec 2018 | A1 |
20190240504 | Brachman et al. | Aug 2019 | A1 |
20200047001 | Nakaji et al. | Feb 2020 | A1 |
20200206372 | Aston et al. | Jul 2020 | A1 |
20200261740 | Baker et al. | Aug 2020 | A1 |
20200261741 | Herskovic | Aug 2020 | A1 |
20200406059 | Kelson et al. | Dec 2020 | A1 |
20210008233 | Kelson et al. | Jan 2021 | A1 |
20210128945 | Schmidt et al. | May 2021 | A1 |
20210154340 | Kelson et al. | May 2021 | A1 |
20210183492 | Park | Jun 2021 | A1 |
20210236850 | Baker et al. | Aug 2021 | A1 |
20210353960 | Sienko et al. | Nov 2021 | A1 |
20210370083 | Giladi et al. | Dec 2021 | A1 |
20210379096 | Domankevich et al. | Dec 2021 | A1 |
20220096854 | Carlson | Mar 2022 | A1 |
20220184418 | Arazi et al. | Jun 2022 | A1 |
20220212035 | Kelson et al. | Jul 2022 | A1 |
Number | Date | Country |
---|---|---|
11 2013 027841 2 | Apr 2012 | BR |
2835065 | Feb 2018 | CA |
2834559 | Nov 2018 | CA |
3017174 | Jan 2020 | CA |
613 528 | May 1935 | DE |
0 292 630 | Aug 1995 | EP |
0 906 769 | Apr 1999 | EP |
2701803 | Aug 2018 | EP |
3456384 | Mar 2019 | EP |
S52-9424 | Jul 1975 | JP |
H09-028810 | Apr 1997 | JP |
2001-266903 | Sep 2001 | JP |
3095304 | Jul 2003 | JP |
2007-512112 | May 2007 | JP |
2009-515603 | Apr 2009 | JP |
2010-536529 | Dec 2010 | JP |
6365983 | Jul 2018 | JP |
WO 2007106531 | Sep 2007 | WO |
WO 2012100206 | Jul 2012 | WO |
WO 2012149580 | Nov 2012 | WO |
WO 2016171961 | Oct 2016 | WO |
WO 2016179420 | Nov 2016 | WO |
Entry |
---|
Cole, P.D., et al., “A comparative long-term assessment of four soft tissue supplements”. Anesthetic Surg J. 31 (6). 674-681, 2011. |
International Search Report; International Application No. PCT/US2012/035907, dated Sep. 26, 2012; 3 pages. |
International Search Report; International Application No. PCT/US2012/035909, dated Aug. 30, 2012; 3 pages. |
Crepeau, R.H., et al., “Image Processing of Imperfect Protein Arrays: Sectioned Crystals and Tubulin Sheets and Rings”. Elec. Microsc. Soc. Amer. Proc. 40:84-87, 1982. |
Crepeau, R.H., et al., “Reconstruction of imperfectly ordered zinc-induced tubulin sheets using cross-correlation and real space averaging”. Ultramicroscopy, 6, 7-18, 1981. |
Dagnew, E., et al., “Management of newly diagnosed single brain metastasis using resection and permanent iodine-125 seeds without initial whole-brain radiotherapy: a two institution experience”. Neurosurg Focus. 15; 22(3):E3, 2007. |
Delaney, T.F., et al., “Intraoperative dural irradiation by customized 192 iridium and 90 Yttrium brachytherapy plaques”. Int. J. Radiat Oncol Biol Phys. 57(1): 239-245, 2003. |
Ewersten, et al., “Biopsy Guided by Real-Time Sonography Fused with MRI: A Phantom Study”, American Journal of Roentgenology. 2008; 190: 1672-1674. 10.2214/AJR.07.2587. |
Gutin, P.H., et al., “A coaxial catheter system for after loading radioactive sources for the interstitial irradiation of brain tumors. Technical note”. J. Neurosurg 56: 734-735, 1982. |
Gutin, P.H., et al., “Brachytherapy of recurrent tumors of the skull base and spine with iodine-125 sources”. Neurosurgery 20:938-945, 1987. |
Hamilton, A.J., et al., “The use of gold foil wrapping for radiation protection of the spinal cord for recurrent tumor therapy”. Int. J. Radiat Oncol Biol Phys. 32(2):507-511, 1995. |
Hilaris, B.S., et al., “Interstitial irradiation for unresectable carcinoma of the lung”. Ann Thoracic Surg; 20:491-500, 1975. |
Hilaris, B.S., et al., “Intraoperative radiotherapy in stage I and II lung cancer”. Semin Surg Oncol. 3:22-32, 1987. |
Huang, K., et al., “Surgical resection and permanent iodine-125 brachytherapy for brain metastases”. J. Neurooncol. 91:83-93, 2009. |
Jenkins, H.P., et al., “Clinical and experimental observations on the use of a gelatin sponge or foam”. Surg 20:124-132, 1946. |
Kneschaurek, P. et al.: “Die Flabmethode Zur Intraoperativen Bestrahlung. Öthe Flab-Method for Intraoperative Radiation Therapy”, Strahlentherapie und Oknologie, Urban Und Vogel, Muenchen, DE, vol. 171, No. 2; Feb. 1, 1995, pp. 61-69, XP000610565, ISSN:0179-7158. |
Marchese, M.J., et al., “A versatile permanent planar implant technique utilizing iodine-125 seeds imbedded in gelfoam”. Int J Radiat Oncol Biol Phys 10:747-751, 1984. |
Miller, S., et al., “Advances in the virtual reality interstitial brachytherapy system.” Engineering Solutions for the Next Millenium. 1999 IEEE Canadian Conference on Electrical and Computer Engineering (Cat. No. 99TH8411). vol. 1. IEEE, 1999. |
Murphy, M.K., et al., “Evaluation of the new cesium-131 seed for use in low-energy x-ray brachytherapy”. Med Phy 31(6): 1529-1538, Jun. 2004. |
Nori, D., et al., “Intraoperative brachytherapy using Gelfoam radioactive plaque implants for resected stage III non-small-cell lung cancer with positive margin: A pilot study”. J Surg Oncol. 60:257-261, 1995. |
Parashar, B., et al., “Cesium-131 permanent seed brachytherapy: Dosimetric evaluation and radiation exposure to surgeons, radiation oncologists, and staff”. Brachytherapy. 10:508-511, 2011. |
Patel, S., et al., “Permanent iodine-125 interstitial implants for the treatment of recurrent Glioblastoma Multiforme”. Neurosurgery 46 (5) 1123-1128, 2000. |
Rivard, M.J., “Brachytherapy dosimetry parameters calculated for a 131 Cs source”. Med Phys. 34(2): 754-765, 2007. |
Rogers, C.L., et al., “Surgery and permanent 125-1 seed paraspinal brachytherapy for malignant tumors with spinal cord compression”. Int. J. Radial Oncol Biol Phys. 54(2): 505-513, 2002. |
Wernicke, A.G., et al., “Feasibility and safety of Gliasite brachytherapy in the treatment of CNS tumors following neurosurgical resection”. J. Cancer Res Ther. 6(1), 65-74, Jan.-Mar. 2010. |
CivaSheet; “Precision Therapy Without the Beam”; CivaTech Oncology Inc.; CivaTech; https://civatechoncology.com/professionals/civasheet/2 pages; Accessed on Oct. 2018. |
CivaSheet; “Precision Therapy Without the Beam”; CivaTech Oncology Inc.; CivaTech; https://civatechoncology.com/products-2/products/; 5 pages; Accessed on Oct. 2018. |
Aima, Manik et al.; “Dosimetric Characterization of a New Directional Low-Dose Rate Brachytherapy Source”; Department of Medical Physics; Mar. 11, 2018; 32 pages. |
Rivard, Mark J.; “A Directional Pd Brachytherapy Device: Dosimetric Characterization and Practical Aspects for Clinical Use”; Department of Radiation Oncology; Brachytherapy 16 (2017) pp. 421-432. |
Office Action dated Apr. 2, 2015; European Patent Application No. 12724426.7. |
Office Action dated Oct. 30, 2015; European Patent Application No. 12724426.7; 4 pages. |
Office Action dated Feb. 9, 2016; Japanese Application No. 2014-508190; 7 pages including english translation. |
International Search Report; International Application No. PCT/US2016/031035; filed May 5, 2016; 15 pages; dated Aug. 5, 2016. |
International Search Report and Written Opinion; International Application No. PCT/US2016/027143, filed Apr. 12, 2016; dated Aug. 25, 2016; 7 pages. |
Decision of Rejection dated Feb. 4, 2016, Japanese Patent Application No. 2014-508190 with English Translation; 4 pages. |
Search and Examination Report; Application No. P1140/13; Filed on Oct. 24, 2013 (PCT dated Apr. 30, 2012); 10 pages. |
Summons to Attend Oral Proceedings dated Aug. 18, 2017; European Application No. 12724426.7; 5 pages. |
Office Action dated Nov. 2, 2017; European Patent Application No. 12724427.5; 4 pages. |
Extended European Search Report; Application No. 18186392.9; dated Jan. 7, 2019; 7 pages. |
Number | Date | Country | |
---|---|---|---|
20210228905 A1 | Jul 2021 | US |
Number | Date | Country | |
---|---|---|---|
62427456 | Nov 2016 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 15824182 | Nov 2017 | US |
Child | 17114976 | US |